

Analyte Health Launches IBS-IBD Test with IQuity

Partnership Expands Access to Cutting-Edge Diagnostic Test For Irritable Bowel Syndrome and Inflammatory Bowel Disease

Analyte Health

www.analytehealth.com

Media Contact:

Christina Kline

312.477.3037

christina.kline@analytehealth.com

Company Facts:

- Founded 2009
- Headquarters Chicago, IL
- 60 employees
- Privately held
- Named Healthcare Tech Outlook Top 10 Telemedicine Provider for 2017
- Net Promoter Score > 70%
- Operating brands
 - STDTestExpress.com
 - HealthTestExpress.com

CHICAGO, IL – February 5, 2018 – [Analyte Health](#), the leading platform connecting patients to diagnostic services, announced today they are now offering access to the Isolate**IBS-IBD**™ test through an expansion of their partnership with IQuity, Inc.

The ground-breaking RNA blood test, Isolate**IBS-IBD**™, is now available through Analyte Health's "[Health Test Express](#)" website, and helps providers diagnose whether patients are suffering from irritable bowel syndrome (IBS) or inflammatory bowel disease (IBD), distinguishing between Crohn's disease and ulcerative colitis.

According to the American College of Gastroenterology, IBS affects between 10-15 percent of the US population, more than 30 million people, yet less than half of them are properly diagnosed. Similarly, Inflammatory Bowel Disease, which includes both Crohn's Disease and Ulcerative Colitis, affects more than 1.6 million Americans, and also has challenges in proper diagnosis.

"Given the prevalence of IBS and IBD in the US population, and the historical challenges of acquiring a timely and accurate diagnosis, we are thrilled to be able to use this innovative test to help providers and patients achieve clarity around their medical conditions," said Frank Cockerill, MD, Chief Medical Officer of Analyte Health.

The Isolate**IBS-IBD** test uses a simple blood draw, collected in the comfort of a patient's own home. Because of this, it can be ordered and interpreted more quickly and conveniently by a much broader range of providers. This means that patients and providers can then take a more informed approach with specialist physicians, once the initial results from the Isolate**IBS-IBD** test are reviewed.

"Isolate**IBS-IBD**™ offers an accurate new tool for patients and providers to identify Irritable Bowel Syndrome (IBS) or Inflammatory Bowel Disease (IBD) at the earliest onset of symptoms, and to distinguish among IBS, Crohn's and ulcerative colitis." says Chase Spurlock, PhD, CEO of IQuity, Inc. "The earlier a patient receives an accurate diagnosis, the faster an appropriate treatment plan can be developed with their provider.

The Isolate**IBS-IBD**™ test uses a unique, patent-pending RNA expression analysis that delivers greater than 90% accuracy. Existing testing technologies rely on a combination of blood, stool, and/or tissue samples, and are often more expensive and difficult to obtain.

The Isolate**IBS-IBD**™ test is the second test from IQuity made available on the Health Test Express web site, joining the existing offering of the Isolate**MS** test, which helps providers diagnose multiple sclerosis earlier and more quickly. A third innovative test, Isolate**Fibromyalgia**™, is expected to be made available within the next 2-3 months.

About Analyte Health

Analyte Health is the leading national company empowering patients to acquire and understand healthcare diagnostic information as conveniently, confidentially, and cost effectively as possible. By combining a national network of patient diagnostic service centers, at-home collection kits, a family of online digital assets, and a national telehealth footprint, Analyte Health is helping thousands of consumers every week, and has delivered more than 2.2 million test results since its inception. Analyte Health works with pharmaceutical companies, telehealth providers, diagnostic companies and other healthcare stakeholders to drive clinical compliance and responsible health awareness for consumers.

Source: www.analytehealth.com

About IQity

IQity is a data science company that uses genomics and proprietary healthcare data to detect and monitor chronic diseases. The company's initial product offerings include its RNA-based Isolate™ tests developed using proprietary machine learning algorithms capable of 'ruling in' or 'ruling out' specific diseases. The accuracy of these methods at the earliest onset of symptoms exceeds 90% and offers providers the ability to shorten the diagnostic process. IQity will perform the tests in its CLIA-certified laboratory in Nashville, TN.

Source: www.iqity.com

###